USE OF L-CARNITINE IN GENERAL MEDICAL PRACTICE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper presents the results of a number of experimental and clinical studies proving the prospects for using L-carnitine in the clinic of internal diseases. Due to its antioxidant and antihypoxant properties, L-carnitine used in addition to the main etiopathogenetic therapy is prescribed by cardiologists, nephrologists, neurologists, and gerontologists. The experimental studies previously conducted by the authors showed no effect of L-carnitine on cytochrome P450 3A4 activity, which lowers the risk of P450 (CYP) 3A4 metabolic drug interactions. When used as part of comprehensive pharmacotherapy, L-carnitine has an increased safety profile in comorbid patients taking the drug.

Full Text

Restricted Access

About the authors

Zh. Sizova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: sizova-klinfarma@mail.ru
Professor, MD

E. Shikh

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Professor, MD

A. Makhova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Candidate of Medical Sciences

References

  1. Кукес В.Г., Сычев Д.А. Персонализированная медицина: новые возможности для пoвышeния бeзoпacнocти фapмaкoтepaпии // Ремедиум. - 2010; 10: 38-40
  2. Мaxoвa A.A. Влияние нaгpyзoчныx доз витaминoв группы B нa фapмaкoкинeтикy и фapмaкoдинaмикy НПВП. Дис. ... канд. мeд. нayк. М., 2010; 107 с.
  3. Rebouche C Carnitine. In: Shils M.E., Shike M., Ross A.C., Caballero B., Cousins R.J., eds. Modern Nutrition in Health and Disease. 10th ed. / Philadelphia: Lippincott, Williams & Wilkins, 2006; 537-44.
  4. Rebouche C. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism // Ann. NY Acad. Sci. - 2004; 1033: 30-41.
  5. De Grandis D., Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabeic neuropathy. A long-term, randomised, doubleblind, placebo-controlled study // Drugs RD. - 2002; 3 (4): 223-31.
  6. Gross C., Henderson L., Savaiano D. Uptake of L-carnitine, D-carnitine and acetyl-L-carnitine by isolated guinea-pig enterocytes // Biochim Biophys Acta. - 1986; 886 (3): 425-33.
  7. Foster D. The role of the carnitine system in human metabolism // Ann. NY Acad. Sci. - 2004; 1033: 1-16.
  8. Асташкин Е.И., Глезер М.Г. Роль L-карнитина в энергетичесокм обмене кардиомиоцитов и лечении заболеваний сердечно-сосудистой системы // Кардиология и сердечно-сосудистая хирургия. - 2012; 6 (2): 58-65
  9. Lombard K., Olson A., Nelson S. et al. Carnitine status of lactoovovegetarians and strict vegetarian adults and children // Am. J. Clin. Nutr. - 1989; 50 (2): 301-6.
  10. Nezu J., Tamai I., Oku A. et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter // Nat Genet. - 1999; 21 (1): 91-4.
  11. Stanley C. Carnitine deficiency disorders in children // Ann. NY Acad. Sci. - 2004; 1033: 42-51.
  12. Seim H., Eichler K., Kleber H. L(-)-Carnitine and its precursor, gamma-butyrobetaine. In: Kramer K., Hoppe P., Packer L., eds. Nutraceuticals in Health and Disease Prevention / New York: Marcel Dekker, Inc, 2001; 217-56.
  13. Pons R., De Vivo D. Primary and secondary carnitine deficiency syndromes // J. Child Neurol. - 1995; 10 (Suppl. 2): 8-24.
  14. Calvani M., Benatti P., Mancinelli A. et al. Carnitine replacement in end-stage renal disease and hemodialysis // Ann. NY Acad. Sci. - 2004; 1033: 52-66.
  15. Food and Nutrition Board, Institute of Medicine. Vitamin C. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids / Washington D.C.: National Academy Press, 2000; 95-185.
  16. Costell M., O'Connor J., Grisolia S. Age-dependent decrease of carnitine content in muscle of mice and humans // Biochem. Biophys. Res. Commun. - 1989; 161 (3): 1135-43.
  17. Hagen T., Ingersoll R., Wehr C. et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity // Proc. Natl. Acad. Sci. USA. - 1998; 95 (16): 9562-6.
  18. Pesce V., Fracasso F., Cassano P. et al. Acetyl-L-carnitine supplementation to old rats partially reverts the age- related mitochondrial decay of soleus muscle by activating peroxisome proliferator-activated receptor gamma coactivator1alpha-dependent mitochondrial biogenesis // Rejuvenation Res. - 2010; 13 (2-3): 148-51.
  19. Gomez L., Heath S., Hagen T. Acetyl-l-carnitine supplementation reverses the age-related decline in carnitine palmitoyltransferase 1 (CPT1) activity in interfibrillar mitochondria without changing the l-carnitine content in the rat heart // Mech. Ageing Dev. - 2012; 133 (2-3): 99-106.
  20. Hagen T., Liu J., Lykkesfeldt J. et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress // Proc. Natl. Acad. Sci. USA. - 2002; 99 (4): 1870-5.
  21. Liu J., Head E., Gharib A. et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alphalipoic acid // Proc. Natl. Acad. Sci. USA. - 2002; 99 (4): 2356-61.
  22. Davini P., Bigalli A., Lamanna F. et al. Controlled study on L-carnitine therapeutic efficacy in post-infarction // Drugs Exp. Clin. Res. - 1992; 18 (8): 355-65.
  23. Xue Y., Wang L., Liu H. et al. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction // Cardiovasc. Drugs Ther. - 2007; 21 (6): 445-8.
  24. Iyer R., Gupta A., Khan A. et al. Does left ventricular function improve with L-carnitine after acute myocardial infarction? // J. Postgrad. Med. - 1999; 45 (2): 38-41.
  25. Colonna P., Iliceto S. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico // Am. Heart J. - 2000; 139 (2 Pt. 3): 124-30.
  26. Iliceto S., Scrutinio D., Bruzzi P. et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial // J. Am. Coll. Cardiol. - 1995; 26 (2): 380-7.
  27. Tarantini G., Scrutinio D., Bruzzi P. et al. Metabolic treatment with L-Carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial // Cardiology. - 2006; 106 (4): 215-23.
  28. Семиголовский Н.Ю. Верцинский Е.К., Азанов Б.А. и др. Положительные инотропные свойства левокарнитина при синдроме малого выброса у больных острым инфарктом миокарда // Кардиология и сердечно-сосудистая хирургия. - 2013; 3: 43-6
  29. Глезер М.Г., Киселева А.Е., Асташкин Е.И. Влияние L-карнитина на дисперсию интервала QT у пациентов с острым коронарным синдромом // Кардиология. - 2015; 55 (3): 4-9
  30. Глезер М.Г., Киселева А.Е., Асташкин Е.И. Влияние L-карнитина на ЧCC и QTc у пациентов с острым коронарным синдромом // Сердце. - 2015; 14 (2/82): 78-84
  31. Глезер М.Г., Киселева А.Е., Прокофьева Е.Б. и др. Влияние L-карнитина на эхокардиографические показатели у пациентов с острым коронарным синдромом // Сердечная недостаточность. - 2015; 16 (4): 234-40
  32. Асташкин Е.И., Глезер М.Г. Влияние L-карнитина на оксидативный стресс при сердечно-сосудистых заболеваниях // Мед. совет. - 2016; 10: 94-100
  33. Асташкин Е.И., Глезер М.Г., Орехова Н.С. и др. Влияние L-карнитина на образование радикалов кислорода фагоцитами крови пациентов с постинфарктным кардиосклерозом // Кардиоваскулярная терапия и профилактика. - 2016; 15 (5): 28-32
  34. Rizos I. Threeyear survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration // Am. Heart J. - 2000; 139 (2 Pt. 3): 120-3.
  35. Xiaolong Song, Huiyan Qu, Zongguo Yang et al. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials // BioMed Research International. - 2017; 2017: Article ID 6274854, 11 p. doi: 10.1155/2017/6274854.
  36. Cacciatore L., Cerio R., Ciarimboli M. et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study // Drugs Exp. Clin. Res. - 1991; 17 (4): 225-35.
  37. Cherchi A., Lai C., Angelino F. et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study // Int. J. Clin. Pharmacol. Ther. Toxicol. - 1985; 23 (10): 569-72.
  38. Iyer R., Khan A., Gupta A. et al. L-carnitine moderately improves the exercise tolerance in chronic stable angina // J. Assoc. Physicians India. - 2000; 48 (11): 1050-2.
  39. DiNicolantonio J., Lavie C., Fares H. et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and metaanalysis // Mayo Clin. Proc. - 2013; 88 (6): 544-51.
  40. Guarnieri G., Situlin R., Biolo G. Carnitine metabolism in uremia // Am. J. Kidney Dis. - 2001; 38 (4 Suppl. 1): 63-7.
  41. Hurot J., Cucherat M., Haugh M. et al. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review // J. Am. Soc. Nephrol. - 2002; 13 (3): 708-14.
  42. Kazmi W., Obrador G., Sternberg M. et al. Carnitine therapy is associated with decreased hospital utilization among hemodialysis patients // Am. J. Nephrol. - 2005; 25 (2): 106-15.
  43. Weinhandl E., Rao M., Gilbertson D. et al. Protective effect of intravenous levocarnitine on subsequent-month hospitalization among prevalent hemodialysis patients, 1998 to 2003 // Am. J. Kidney Dis. - 2007; 50 (5): 803-12.
  44. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation // Am. J. Kidney Diseases. - 2000; 35 (6 Suppl. 2): 1-140.
  45. Eknoyan G., Latos D., Lindberg J. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference // Am. J. Kidney Dis. - 2003; 41 (4): 868-76.
  46. Schreiber B. Safety of oral carnitine in dialysis patients // Semin Dial. - 2002; 15 (1): 7.
  47. Wei X.-J., Han M., Wei G.-C. et al. Prognostic value of cerebrospinal fluid free fatty acid levels in patients with acute ischemic stroke // Frontiers in Human Neuroscience. - 2015; 9: 402. doi: 10.3389/fnhum.2015.00402
  48. Головкин В., Зуев А., Привалова М. и др. Когнитивные нарушения и кардиореспираторная дисфункция при дисциркуляторной энцефалопатии с кардиоцеребральным синдромом // Врач. - 2018; 29 (4): 51-3
  49. Гусев Е.И., Кузин В.М., Колесникова Т.Н. и др. Карнитин - ведущий фактор регенерации нервной ткани // Медицинский информационный вестник. - 1999 (февраль): 11-23
  50. Бодыхов М.К., Стаховская Л.В., Салимов К.А. и др. Оценка безопасности и эффективности препарата «Элькар» (левокарнитин) у пациентов в остром периоде ишемического инсульта в каротидной системе // РМЖ. Неврология. - 2011; 11: 3-6
  51. Чичановская Л.В., Бахарева О.Н., Сорокина К.Б. Исследование безопасности и эффективности L-карнитина у больных в раннем восстановительном периоде ишемического инсульта // Журнал неврологии и психиатрии им. С.С. Корсакова. - 2017; 12 (Вып. 2): 65-9
  52. Makhova A., Shich E., Kukes V. etal. Electroanalysis of cytochrome P450 3A4 catalytic properties with nanostructured electrodes: the influence of vitamin B group on diclofenac metabolism // BioNanoScience. - 2011; 1 (1-2): 46-52
  53. Махова А.А., Шумянцева В.В., Ших Е.В. и др. Регуляция активности ферментов метаболизма лекарственных препаратов - цитохромов Р450 3А4 и 2С9 - биологически активными соединениями // Молекулярная медицина. - 2013; 5: 49-53

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies